Key Highlights

  • ICON plc (NASDAQ:ICLR) traded at USD 195.00, up 6.57%, in pre-market trading on Wednesday, October 28, 2026, after its third quarter 2026 results came out following the close on Tuesday, October 27, 2026.
  • Third quarter revenue was USD 2,024.8 million, down 2.9% year on year. GAAP net income was USD 122.1 million, or USD 1.58 per diluted share, and adjusted diluted EPS came in at USD 2.66 against USD 3.20.
  • Backlog reached USD 24.5 billion, up 4.8% from the prior quarter. Net business wins totalled USD 3,150 million, and full year 2026 revenue guidance was raised to USD 8,100 million to USD 8,200 million.
  • The quote is a pre-market snapshot on thin volume that can change before the 9:30 a.m. ET open, and the Federal Reserve decision is due later on the same Wednesday.

Pre-Market Move and Its Trigger

ICON plc (NASDAQ:ICLR) is an Irish clinical research organisation that runs drug development trials for pharmaceutical and biotechnology sponsors. Its USD 195.00 pre-market price, up 6.57%, came in the snapshot for Wednesday, October 28, 2026. The trigger was the third quarter 2026 earnings release, issued at 4:43 p.m. ET on Tuesday, October 27, 2026, after the prior session closed. The release paired a year on year revenue decline with a larger backlog, stronger net business wins, a raised revenue outlook and an enlarged share buyback authorisation. The gain therefore seems to reflect the forward indicators rather than the quarterly earnings alone, which is an inference. Prices can change before the open at 9:30 a.m. ET.

How the Quarter Frames the Move

In its release of Tuesday, October 27, 2026, ICON reported third quarter revenue of USD 2,024.8 million, down 2.9% year on year. Adjusted EBITDA, which strips out interest, tax, depreciation and one-off charges, was USD 336.9 million, a fall of 13.1%. Adjusted diluted EPS was USD 2.66, up 3.9% from the second quarter but below USD 3.20 a year earlier. Free cash flow reached USD 302.4 million, and the company bought back USD 400.0 million of stock while raising its authorisation to USD 750.0 million. Net business wins of USD 3,150 million against revenue imply a book-to-bill ratio of about 1.56, a simple division of two published figures. Full year 2026 adjusted diluted EPS guidance was narrowed to USD 10.35 to USD 10.65 from USD 10.00 to USD 11.00, with the midpoint unchanged.

Risks and Signals to Track

The positive case rests on backlog of USD 24.5 billion, strong order intake, the raised revenue range and cash returned to shareholders. The negative case rests on the revenue decline, the 13.1% fall in adjusted EBITDA and an adjusted EPS midpoint that stayed at USD 10.50. Named risks include the cancellation or delay of sponsor contracts sitting in backlog, pricing pressure among research organisations and leverage after the USD 2.15 billion notes offering priced on Thursday, August 6, 2026. A pre-market move on limited volume could also reverse at the open. Investors should watch the Federal Reserve decision later that day, the company earnings call and any update to full year guidance in the next quarterly release.

Where Things Stand

The short answer is that ICON plc (NASDAQ:ICLR) rose 6.57% before the open because its release of Tuesday, October 27, 2026 combined a backlog of USD 24.5 billion and net business wins of USD 3,150 million with a higher revenue outlook, even though third quarter revenue fell 2.9%. The headline figure is the full year revenue range of USD 8,100 million to USD 8,200 million, up from USD 7,850 million to USD 8,150 million. The next catalysts are the Federal Reserve decision due later on Wednesday, October 28, 2026 and the fourth quarter results. Pre-market prices are snapshots and can change, and this is not investment advice.